A complete overview of all the HD clinical trials will be given; the preliminary results on the ‘pridopidine’ compound will be illustrated; an update on the gene therapy trial will be presented.
Mr Mohammed Al-Hajri – President of the Oman HD Association- has been invited as a speaker to share the Oman Huntington Association experience with the Italian families. This is a great opportunity to get updated information on research to be shared with the Omani families, once Mr Al-Hajri will be back in Muscat.]]>
Read more on:
Official press release of Teva on:
This is a video by Italian League for Research on Huntington and related diseases (LIRH):]]>
‘Postacards from Palm Springs’
A very interesting report on the 2016 conference is available also in Arabic at this link:
More on http://www.euro-hd.net/html/ehdn2016/announcement and on http://eurohuntington.org]]>
SD-809 (deutetrabenazine) is an investigational, oral, small molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is designed to regulate the levels of a specific neurotransmitter, dopamine, in the brain. SD-809 is being developed for the treatment of ‘chorea’ associated with Huntington disease, a neurodegenerative movement disorder that impacts cognition, behavior, and movements. The FIRST-HD study showed a favorable safety and tolerability profile, including low rates of depression, somnolence, akathisia/restlessness and anxiety. The safety and tolerability experience observed in the ARC-HD study was consistent with the experience observed in the FIRST-HD study. The most commonly reported adverse events in ARC-HD patients were somnolence, fall, and nasopharyngitis.
Read more on http://www.tevapharm.com/news/?itemid=%7BB77B4464-664B-4DC5-8373-F7D040CE2327%7D]]>
This is the second time in 2015, as the Neurogenetics Clinic has been opened for HD patients also in February.
The Neurogentics Clinic for HD is supported by the Omani Ministry of Health (MOH), the National Genetic Centre (dr. Anna Rajab) and the Neurology Unit (dr. Jaber Al Khaboori), at the Royal Hospital In Muscat.
Ferdinando Squitieri hai been studying and treating HD over the last 30 years. He is Head of the Research and Cure for Huntington and Rare Diseases Unit at IRCCS Fondazione Casa Sollievo della Sofferenza, Opera di San Pio da Pietrelcina in San Giovanni Rotondo (FG) (Research Institute focused on herereditary diseases:http://www.operapadrepio.it/ ) and at Istituto CSS Mendel (Genetic Institute:http://www.css-mendel.it/ ) in Rome. He is also scientific director of LIRH Foundation, the Italian not for profit League for Research on Huntington and related diseases (www.lirh.it), which is partner of the Oman HD Association.]]>
Prof Squitieri visits HD patients at the National Genetic Center, Royal Hospital in Muscat, in the morning from h 9.00 to h 13.00.